<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="bap1-tpds" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">bap1-tpds</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">BAP1</italic> Tumor Predisposition Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonyms: <italic toggle="yes">BAP1</italic> Cancer Syndrome; <italic toggle="yes">BAP1</italic>-TPDS; Cutaneous/Ocular Melanoma, Atypical Melanocytic Proliferations, and Other Internal Neoplasms (COMMON Syndrome)</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pilarski</surname>
            <given-names>Robert</given-names>
          </name>
          <degrees>MS,LGC, MSW</degrees>
          <aff>Department of Internal Medicine and Comprehensive Cancer Center<break/>The Ohio State University<break/>Columbus, Ohio</aff>
          <email>robert.pilarski@osumc.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rai</surname>
            <given-names>Karan</given-names>
          </name>
          <degrees>BS</degrees>
          <aff>Department of Internal Medicine and Comprehensive Cancer Center<break/>The Ohio State University<break/>Columbus, Ohio</aff>
          <email>karan.rai@osumc.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cebulla</surname>
            <given-names>Colleen</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Ophthalmology<break/>The Ohio State University<break/>Columbus, Ohio</aff>
          <email>colleen.cebulla@osumc.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdel-Rahman</surname>
            <given-names>Mohamed</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Ophthalmology<break/>The Ohio State University<break/>Columbus, Ohio</aff>
          <email>mohamed.abdel-rahman@osumc.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>13</day>
          <month>10</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="li-ar" document-type="chapter">Autosomal Recessive Congenital Ichthyosis</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="brca1" document-type="chapter"><italic toggle="yes">BRCA1-</italic> and <italic toggle="yes">BRCA2</italic>-Associated Hereditary Breast and Ovarian Cancer</related-object>
      <abstract id="bap1-tpds.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">BAP1</italic> tumor predisposition syndrome (<italic toggle="yes">BAP1</italic>-TPDS) is associated with an increased risk for the specific skin lesion &#x02013; atypical Spitz tumors &#x02013; and the following cancers, in descending order of frequency: uveal (eye) melanoma (UM), malignant mesothelioma (MMe), cutaneous melanoma (CM), clear cell renal cell carcinoma (ccRCC), and basal cell carcinoma (BCC). Affected individuals can have more than one type of primary cancer. In general the median age of onset of these tumors is younger than in the general population. UM tends to be a more aggressive class 2 tumor with higher risk for metastasis and reduced survival compared to UM that occurs in the general population. However, because of the limited number of families reported to date, the penetrance, natural history, and frequencies of the <italic toggle="yes">BAP1</italic>-associated tumors are yet to be determined.</p>
          <p>Other suspected but unconfirmed tumors in <italic toggle="yes">BAP1</italic>-TPDS include (in alphabetic order): breast cancer, cholangiocarcinoma, non-small cell lung adenocarcinoma (NSCLC), meningioma, and neuroendocrine carcinoma.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">BAP1</italic>-TPDS is established in a proband by identification of a heterozygous germline pathogenic variant in <italic toggle="yes">BAP1</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> The treatments for <italic toggle="yes">BAP1</italic>-TPDS tumors are those used in standard practice. UM: Because of the increased aggressiveness of <italic toggle="yes">BAP1</italic>-related uveal melanoma, all uveal melanomas should be managed as the more aggressive class 2 or monosomy 3 tumors. MMe is highly refractory to conventional therapies including aggressive surgical intervention and multimodality strategies; thus, a cure is unlikely.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> UM: avoid arc-welding. No data exist regarding benefit of sunglasses for reduction of UM risk. MMe: avoid asbestos exposure and smoking. CM and BCC: limit sun exposure, use sunscreen and protective clothing, and have regular dermatologic examinations.</p>
          <p><italic toggle="yes">Surveillance:</italic> UM: yearly dilated eye examinations and imaging by an ocular oncologist beginning around age 11 years. MMe: No screening modalities exist; however, annual physical examination is recommended. If an abdominal MRI is to be performed as recommended for ccRCC, consider evaluation of the peritoneum and pleura as well. Although some physicians recommend spiral chest CT for asymptomatic persons with a history of exposure to asbestos, others do not, given the possible increased risk of cancer from radiation exposure. CM, basal cell carcinoma, ASTs: Annual full-body dermatologic examinations beginning around age 20 years. ccRCC: annual abdominal ultrasound examination; consider annual urinalysis and abdominal MRI every two years.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> see <italic toggle="yes">Prevention of primary manifestations</italic>.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Clarify the genetic status of apparently asymptomatic older and younger at-risk relatives by molecular genetic testing for the <italic toggle="yes">BAP1</italic> pathogenic variant in the family in order to identify as early as possible those who would benefit from prompt initiation of screening and preventive measures.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">BAP1</italic>-TPDS is inherited in an autosomal dominant manner. To date, most individuals diagnosed with <italic toggle="yes">BAP1</italic>-TPDS have an affected parent; the proportion of <italic toggle="yes">BAP1</italic>-TPDS caused by a <italic toggle="yes">de novo</italic> pathogenic variant is unknown. Each child of an individual with <italic toggle="yes">BAP1</italic>-TPDS has a 50% chance of inheriting the <italic toggle="yes">BAP1</italic> pathogenic variant; however, penetrance appears to be incomplete and the types of <italic toggle="yes">BAP1</italic>-related tumors can vary among different members of the same family. Once the germline <italic toggle="yes">BAP1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk for <italic toggle="yes">BAP1</italic>-TPDS and preimplantation genetic diagnosis are possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="bap1-tpds.Diagnosis">
        <title>Diagnosis</title>
        <p>No diagnostic criteria have been published for the <italic toggle="yes">BAP1</italic> tumor predisposition syndrome (<italic toggle="yes">BAP1</italic>-TPDS).</p>
        <sec id="bap1-tpds.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">BAP1</italic> tumor predisposition syndrome (<italic toggle="yes">BAP1</italic>-TPDS) <bold>should be suspected</bold> in an individual who has EITHER of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Two or more confirmed <italic toggle="yes">BAP1</italic>-TPDS tumors*</p>
              <p>OR</p>
            </list-item>
            <list-item>
              <p>One <italic toggle="yes">BAP1</italic>-TPDS tumor and a first- or second-degree relative with a confirmed <italic toggle="yes">BAP1</italic>-TPDS tumor*</p>
            </list-item>
          </list>
          <p>* Excluding two basal cell cancers and/or cutaneous melanomas, given their high frequency in the general population</p>
          <p>Confirmed <italic toggle="yes">BAP1</italic>-TPDS tumors include the following (in descending order of likelihood):</p>
          <list list-type="bullet">
            <list-item>
              <p>Atypical Spitz tumors (ASTs), which may be the most common manifestation of <italic toggle="yes">BAP1</italic>-TPDS, and may result in the initial identification of a proband. ASTs are skin-colored to reddish-brown, averaging 5 mm in diameter; the histologic findings are between those of a Spitz nevus and a melanoma. Both copies of <italic toggle="yes">BAP1</italic> are inactivated leading to loss of staining for the BAP1 protein on immunohistochemistry.</p>
            </list-item>
            <list-item>
              <p>Uveal (eye) melanoma</p>
            </list-item>
            <list-item>
              <p>Malignant mesothelioma (MMe)</p>
            </list-item>
            <list-item>
              <p>Cutaneous melanoma</p>
            </list-item>
            <list-item>
              <p>Clear cell renal cell carcinoma (ccRCC)</p>
            </list-item>
            <list-item>
              <p>Basal cell carcinoma</p>
            </list-item>
          </list>
          <p>Unconfirmed tumors (with conflicting evidence regarding inclusion in the <italic toggle="yes">BAP1</italic>-TPDS tumor spectrum) include the following (in alphabetic order):</p>
          <list list-type="bullet">
            <list-item>
              <p>Breast cancer</p>
            </list-item>
            <list-item>
              <p>Cholangiocarcinoma</p>
            </list-item>
            <list-item>
              <p>Meningioma</p>
            </list-item>
            <list-item>
              <p>Neuroendocrine tumors</p>
            </list-item>
            <list-item>
              <p>Non-small cell lung adenocarcinoma (NSCLC)</p>
            </list-item>
            <list-item>
              <p>Thyroid cancer</p>
            </list-item>
          </list>
        </sec>
        <sec id="bap1-tpds.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">BAP1</italic>-TPDS <bold>is established</bold> in a proband by identification of a heterozygous germline pathogenic variant in <italic toggle="yes">BAP1</italic> on molecular genetic testing (see <xref ref-type="table" rid="bap1-tpds.T.molecular_genetic_testing_us">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold> or use of a <bold>multi-gene panel</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">BAP1</italic> is performed. To date, no published data exist regarding the benefit (or lack thereof) of doing gene-targeted deletion/duplication analysis if no <italic toggle="yes">BAP1</italic> pathogenic variant is found on sequence analysis.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">BAP1</italic> and other genes of interest (see <xref ref-type="sec" rid="bap1-tpds.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
            </list-item>
          </list>
          <table-wrap id="bap1-tpds.T.molecular_genetic_testing_us" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">BAP1</italic> Tumor Predisposition Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">BAP1</italic>
                  </td>
                  <td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">All variants reported to date&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="bap1-tpds.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="bap1-tpds" object-id="bap1-tpds.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="bap1-tpds.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="bap1-tpds.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="bap1-tpds.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="bap1-tpds.TF.1.4">
                <label>4. </label>
                <p>
                  <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al [2016]</xref>
                </p>
              </fn>
              <fn id="bap1-tpds.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="bap1-tpds.TF.1.6">
                <label>6. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available. Using MLPA, no <italic toggle="yes">BAP1</italic> exon or multiexon deletions/duplications were identified in 20 individuals with uveal melanoma and a family history of uveal melanoma or in ten individuals with uveal melanoma and a personal or family history of renal cell carcinoma [M Abdel-Rahman, unpublished data].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="bap1-tpds.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="bap1-tpds.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">BAP1</italic> tumor predisposition syndrome (<italic toggle="yes">BAP1</italic>-TPDS) is associated with an increased risk for a number of cancers and a specific skin lesion (atypical Spitz tumors). Affected individuals can have more than one type of primary cancer [<xref ref-type="bibr" rid="bap1-tpds.REF.testa.2011.1022">Testa et al 2011</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.aoude.2013b.e72144">Aoude et al 2013b</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.cheung.2015.261">Cheung et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>].</p>
          <p>Because of the limited number of families reported to date and because of the ascertainment bias of the interests of the research groups focusing on uveal melanoma, malignant mesothelioma, and cutaneous melanoma, the penetrance and frequencies of the various <italic toggle="yes">BAP1</italic>-associated tumors are yet to be determined. It has been well established, however, that the following tumor types are associated with <italic toggle="yes">BAP1</italic>-TPDS.</p>
          <p><bold>Atypical Spitz tumors</bold>
<bold>(ASTs).</bold>
<xref ref-type="bibr" rid="bap1-tpds.REF.wiesner.2012.818">Wiesner et al [2012]</xref> categorized these skin lesions as &#x0201c;atypical Spitz tumors&#x0201d;; the authors agree that this is the most appropriate designation (see <xref ref-type="sec" rid="bap1-tpds.Nomenclature">Nomenclature</xref> for other terms used to describe these tumors).</p>
          <p><bold>Uveal melanoma (UM)</bold> is the cancer most commonly reported in persons with <italic toggle="yes">BAP1</italic>-TPDS (31%), and the cancer with the earliest reported age of diagnosis (age 16 years) [<xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>].</p>
          <p>Median age of onset of UM in persons with <italic toggle="yes">BAP1</italic>-TPDS is 51 years, which is younger than the onset of UM in the general population (62 years). The tumors are generally more aggressive class 2 (i.e., high metastatic risk) tumors with higher risk for metastasis and reduced survival [<xref ref-type="bibr" rid="bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>]. In one study, mean length of survival in persons whose uveal melanoma tumor lacked BAP1 expression was 4.74 years compared to 9.97 years in persons whose tumors expressed BAP1 [<xref ref-type="bibr" rid="bap1-tpds.REF.kalirai.2014.1373">Kalirai et al 2014</xref>].</p>
          <p><bold>Malignant mesothelioma (MMe)</bold> is the second most frequent cancer (22%) identified in <italic toggle="yes">BAP1</italic>-TPDS [<xref ref-type="bibr" rid="bap1-tpds.REF.testa.2011.1022">Testa et al 2011</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>].</p>
          <p>Two studies [<xref ref-type="bibr" rid="bap1-tpds.REF.baumann.2015.76">Baumann et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</xref>] have shown that the median age of onset of MMe in individuals with <italic toggle="yes">BAP1</italic>-TPDS was significantly earlier (55 and 58 years, respectively) than that of sporadic MMe (72 and 68 years, respectively).</p>
          <p>Generally, pleural MMe accounts for about 80% and peritoneal MMe constitutes most of the remaining MMe. However, in individuals with <italic toggle="yes">BAP1</italic>-TPDS the ratio of peritoneal to pleural involvement is significantly higher [<xref ref-type="bibr" rid="bap1-tpds.REF.carbone.2015.e1005633">Carbone et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.cheung.2015.261">Cheung et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</xref>]. In <italic toggle="yes">BAP1</italic>-TPDS the majority of peritoneal MMe occurs in women, in contrast to the general population, in which men are more likely to have this tumor type [<xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>].</p>
          <p>In contrast to survival in persons with <italic toggle="yes">BAP1</italic>-related cutaneous melanoma, uveal melanoma, or renal cell carcinoma, survival in persons with <italic toggle="yes">BAP1</italic>-related MMe may be significantly longer [<xref ref-type="bibr" rid="bap1-tpds.REF.de_reyni_s.2014.1323">de Reyni&#x000e8;s et al 2014</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.baumann.2015.76">Baumann et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.carbone.2015.e1005633">Carbone et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</xref>]; however, to date the data are not consistent [<xref ref-type="bibr" rid="bap1-tpds.REF.singhi.2016.14">Singhi et al 2016</xref>].</p>
          <p>Growing evidence suggests that <italic toggle="yes">BAP1</italic> pathogenic variants interact with environmental asbestos exposure to increase the risk for MMe [<xref ref-type="bibr" rid="bap1-tpds.REF.xu.2014.4388">Xu et al 2014</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.kadariya.2016.2836">Kadariya et al 2016</xref>].</p>
          <p><bold>Cutaneous melanoma (CM).</bold> First reported in association with <italic toggle="yes">BAP1</italic>-TPDS in 2011, CM is now known to be the third most common cancer in <italic toggle="yes">BAP1</italic>-TPDS, occurring in 13% of affected individuals [<xref ref-type="bibr" rid="bap1-tpds.REF.wiesner.2011.1018">Wiesner et al 2011</xref>]. Multiple primary cutaneous melanomas are common. The median age of onset of CM in <italic toggle="yes">BAP1</italic>-TPDS is earlier than in the general population (46 vs 58 years). Although it is possible that <italic toggle="yes">BAP1-</italic>related CM is more aggressive than cutaneous melanoma in the general population, to date the data are inconsistent [<xref ref-type="bibr" rid="bap1-tpds.REF.gupta.2015.881">Gupta et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.kumar.2015.1089">Kumar et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>].</p>
          <p><bold>Clear cell renal cell carcinoma (ccRCC).</bold> Heterozygous <italic toggle="yes">BAP1</italic> germline pathogenic variants are specifically associated with an increased risk for ccRCC [<xref ref-type="bibr" rid="bap1-tpds.REF.haas.2014.81">Haas &#x00026; Nathanson 2014</xref>]. Median age of ccRCC diagnosis appears to be younger in persons with <italic toggle="yes">BAP1</italic>-TPDS than in the general population (47 vs 64 years), and length of survival is decreased in persons with <italic toggle="yes">BAP1-</italic>related ccRCC [<xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>]. Histology of these tumors is distinct from tumors not associated with pathogenic variants in <italic toggle="yes">BAP1</italic>, with higher grade at diagnosis and lack of <italic toggle="yes">PBRM1</italic> pathogenic variants (which are common in ccRCC not associated with pathogenic variants in <italic toggle="yes">BAP1</italic>) [<xref ref-type="bibr" rid="bap1-tpds.REF.pe_allopis.2012.751">Pe&#x000f1;a-Llopis et al 2012</xref>].</p>
          <p><bold>Basal cell carcinoma</bold> has recently been confirmed as a tumor in the <italic toggle="yes">BAP1</italic>-TPDS spectrum [<xref ref-type="bibr" rid="bap1-tpds.REF.de_la_fouchardi_re.2015a.273">de la Fouchardi&#x000e8;re et al 2015a</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.mochel.2015.901">Mochel et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.wadt.2015.267">Wadt et al 2015</xref>]. Multiple primary basal cell carcinomas are common. Based on limited information, the median age of diagnosis appears to be around 50 years.</p>
          <p><bold>Other cancers</bold> with some evidence (although inconsistent) supporting inclusion in the <italic toggle="yes">BAP1</italic>-TPDS spectrum are the following (in alphabetic order):</p>
          <list list-type="bullet">
            <list-item>
              <p>Breast cancer [<xref ref-type="bibr" rid="bap1-tpds.REF.testa.2011.1022">Testa et al 2011</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.njauw.2012.e35295">Njauw at al 2012</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.popova.2013.974">Popova et al 2013</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.pilarski.2014.177">Pilarski et al 2014</xref>]</p>
            </list-item>
            <list-item>
              <p>Cholangiocarcinoma [<xref ref-type="bibr" rid="bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.pilarski.2014.177">Pilarski et al 2014</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.wadt.2015.267">Wadt et al 2015</xref>]</p>
            </list-item>
            <list-item>
              <p>Meningioma [<xref ref-type="bibr" rid="bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.cheung.2015.261">Cheung et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.de_la_fouchardi_re.2015b.921">de la Fouchardi&#x000e8;re et al 2015b</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.wadt.2015.267">Wadt et al 2015</xref>]</p>
            </list-item>
            <list-item>
              <p>Neuroendocrine tumors [<xref ref-type="bibr" rid="bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.wadt.2012.815">Wadt et al 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>Non-small cell lung adenocarcinoma (NSCLC) [<xref ref-type="bibr" rid="bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.wadt.2012.815">Wadt et al 2012</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.aoude.2013b.e72144">Aoude et al 2013b</xref>]</p>
            </list-item>
            <list-item>
              <p>Thyroid cancer [<xref ref-type="bibr" rid="bap1-tpds.REF.popova.2013.974">Popova et al 2013</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.mcdonnell.2016.75">McDonnell et al 2016</xref>]</p>
            </list-item>
          </list>
        </sec>
        <sec id="bap1-tpds.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>To date no genotype-phenotype correlations are published for <italic toggle="yes">BAP1-</italic>TPDS.</p>
          <p>Most families (46 of 57) have had a unique <italic toggle="yes">BAP1</italic> pathogenic variant; only five recurrent pathogenic variants have been reported [<xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>] (see <xref ref-type="sec" rid="bap1-tpds.Molecular_Genetics">Molecular Genetics</xref>).</p>
        </sec>
        <sec id="bap1-tpds.Penetrance">
          <title>Penetrance</title>
          <p>The penetrance of the <italic toggle="yes">BAP1</italic>-TPDS appears to be high based on the published literature. In their review <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al [2016]</xref> found that 148/174 (85%) individuals reported with a heterozygous germline <italic toggle="yes">BAP1</italic> pathogenic variant had a cancer diagnosis. However, ascertainment biases in favor of both testing and reporting affected versus unaffected individuals may have inflated this figure. For example, in more than half of the reported families only the proband had been tested. Given these biases, an accurate estimate of penetrance cannot be determined at this time.</p>
        </sec>
        <sec id="bap1-tpds.Nomenclature">
          <title>Nomenclature</title>
          <p>Atypical Spitz tumors have also been called the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Nevoid melanoma-like melanocytic proliferations (NEMMP) [<xref ref-type="bibr" rid="bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>Melanocytic <italic toggle="yes">BAP1</italic>-mutated atypical intradermal tumors (MBAITS) [<xref ref-type="bibr" rid="bap1-tpds.REF.carbone.2012.179">Carbone et al 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>BAPoma [Author, personal observation]</p>
            </list-item>
          </list>
        </sec>
        <sec id="bap1-tpds.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of <italic toggle="yes">BAP1</italic>-TPDS is unknown. A 2015 review identified 57 published families with 174 individuals with <italic toggle="yes">BAP1</italic>-TPDS [<xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>].</p>
          <p>The data on the prevalence of <italic toggle="yes">BAP1</italic>-TPDS in persons with uveal melanoma, mesothelioma, cutaneous melanoma, and familial renal cell carcinoma are limited. The prevalence of <italic toggle="yes">BAP1</italic>-TPDS in persons with other cancers is unknown.</p>
          <p>Of note, in one review 90% of families reported with a germline <italic toggle="yes">BAP1</italic> pathogenic variant met the criteria outlined in <xref ref-type="sec" rid="bap1-tpds.Suggestive_Findings">Suggestive Findings</xref> [<xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>]; whereas germline <italic toggle="yes">BAP1</italic> pathogenic variants are rare in unselected series of individuals with one tumor type or families with multiple members with only one tumor type (i.e., uveal melanoma [<xref ref-type="bibr" rid="bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.turunen.2016.1112">Turunen et al 2016</xref>], mesothelioma [<xref ref-type="bibr" rid="bap1-tpds.REF.testa.2011.1022">Testa et al 2011</xref>], cutaneous melanoma [<xref ref-type="bibr" rid="bap1-tpds.REF.aoude.2015.126">Aoude et al 2015</xref>], or renal cell carcinoma [<xref ref-type="bibr" rid="bap1-tpds.REF.farley.2013.1061">Farley et al 2013</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.popova.2013.974">Popova et al 2013</xref>]).</p>
          <p><bold>Uveal melanoma.</bold> The prevalence of germline <italic toggle="yes">BAP1</italic> pathogenic variants in unselected individuals with uveal melanoma is 1%-2% [<xref ref-type="bibr" rid="bap1-tpds.REF.aoude.2013a.278">Aoude et al 2013a</xref>]; in contrast, the frequency is 20%-30% in persons with uveal melanoma who have a family history of uveal melanoma [<xref ref-type="bibr" rid="bap1-tpds.REF.popova.2013.974">Popova et al 2013</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.gupta.2015.881">Gupta et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.turunen.2016.1112">Turunen et al 2016</xref>].</p>
          <p><bold>Malignant mesothelioma (MMe).</bold> Germline <italic toggle="yes">BAP1</italic> pathogenic variants have been identified in 6% (9/153) to 20% (1/5) of individuals with familial mesothelioma [<xref ref-type="bibr" rid="bap1-tpds.REF.betti.2015.51">Betti et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</xref>]; however they are rare in simplex cases (i.e., a single occurrence of MMe in a family) [<xref ref-type="bibr" rid="bap1-tpds.REF.rusch.2014.271">Rusch et al 2014</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.betti.2015.51">Betti et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.sneddon.2015.103">Sneddon et al 2015</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</xref>].</p>
          <p><bold>Cutaneous melanoma.</bold> A germline <italic toggle="yes">BAP1</italic> heterozygous missense variant was identified in 0.63% of a population-based cohort of 1109 probands with cutaneous melanoma [<xref ref-type="bibr" rid="bap1-tpds.REF.aoude.2015.126">Aoude et al 2015</xref>].</p>
        </sec>
      </sec>
      <sec id="bap1-tpds.Genetically_Related_Allelic_Di">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with germline pathogenic variants in <italic toggle="yes">BAP1</italic>.</p>
        <p>Somatic <italic toggle="yes">BAP1</italic> variants have been found in some of the tumor types that are components of <italic toggle="yes">BAP1</italic>-TPDS as well as in other tumor types. These variants are <bold>not</bold> present in the germline and not heritable. For more details see Molecular Genetics, <xref ref-type="sec" rid="bap1-tpds.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</xref>.</p>
      </sec>
      <sec id="bap1-tpds.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Mutation of other genes can be associated with uveal melanoma, malignant mesothelioma, renal cell carcinoma, and atypical Spitz tumors; however, no other gene is known to be associated with increased risk for the <bold>combination of these cancers</bold>, as is seen in <italic toggle="yes">BAP1</italic> tumor predisposition syndrome (<italic toggle="yes">BAP1</italic>-TPDS).</p>
        <table-wrap id="bap1-tpds.T.disorders_and_genes_to_consi" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Disorders and Genes to Consider in the Differential Diagnosis <italic toggle="yes">BAP1</italic>-TPDS</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Cancer Type/Associated Disorder</th>
                <th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene(s)</th>
                <th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">MOI</th>
                <th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Comments and References</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">Uveal melanoma</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">BRCA2</italic>
                </td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="bap1-tpds.REF.iscovich.2002.42">Iscovich et al [2002]</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.scott.2002.188">Scott et al [2002]</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.sinilnikova.1999.325">Sinilnikova et al [1999]</xref></td>
              </tr>
              <tr>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">Malignant mesothelioma</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">Cutaneous melanoma</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">CDKN2A</italic>
                  <break/>
                  <italic toggle="yes">CDK4</italic>
                  <break/>
                  <italic toggle="yes">MC1R</italic>
                  <break/>
                  <italic toggle="yes">MITF</italic>
                </td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Pancreatic cancer is associated w/mutation of <italic toggle="yes">CDKN2A</italic> [<xref ref-type="bibr" rid="bap1-tpds.REF.marzukaalcal_.2014.381">Marzuka-Alcal&#x000e1; et al 2014</xref>]</td>
              </tr>
              <tr>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">Familial<break/>clear cell<break/>renal cell<break/>carcinoma</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="paragangliomas" document-type="chapter">Hereditary paraganglioma-pheochromocytoma syndromes</related-object>
                </td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SDHA</italic>
                  <break/>
                  <italic toggle="yes">SDHB</italic>
                  <break/>
                  <italic toggle="yes">SDHC</italic>
                  <break/>
                  <italic toggle="yes">SDHD</italic>
                  <break/>
                  <italic toggle="yes">SDHAF2</italic>
                  <break/>
                  <italic toggle="yes">MAX</italic>
                </td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="vhl" document-type="chapter">Von Hippel-Lindau syndrome</related-object>
                </td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">VHL</italic>
                </td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Translocation chromosome 3</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/144700">OMIM</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MOI = mode of inheritance</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="bap1-tpds.Management">
        <title>Management</title>
        <sec id="bap1-tpds.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">BAP1</italic> tumor predisposition syndrome (<italic toggle="yes">BAP1</italic>-TPDS), the following evaluations are recommended [<xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Atypical Spitz (ATS) tumors, cutaneous melanoma (CM), and/or basal cell carcinoma (BCC).</bold> Full-body skin examination by a dermatologist with excision of any lesions suggestive of an atypical Spitz tumor</p>
            </list-item>
            <list-item>
              <p><bold>Uveal melanoma (UM).</bold> Dilated eye examination and imaging by an ocular oncologist</p>
            </list-item>
            <list-item>
              <p><bold>Malignant mesothelioma (MMe).</bold> No screening modalities exist; however, if an abdominal MRI is to be performed as recommended for ccRCC, consider evaluation of the peritoneum and pleura as well. Although some physicians recommend spiral chest CT for asymptomatic persons with a history of exposure to asbestos, others do not, given the possible increased risk of cancer from radiation exposure.</p>
            </list-item>
            <list-item>
              <p><bold>Clear cell renal cell carcinoma (ccRCC).</bold> Abdominal ultrasound examination, urinalysis, and abdominal MRI (consider also requesting assessment of the pleura and peritoneum)</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="bap1-tpds.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The treatments for <italic toggle="yes">BAP1</italic>-TPDS tumors are those used in standard practice.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Uveal melanoma</bold>. Because of the increased aggressiveness of <italic toggle="yes">BAP1</italic>-related uveal melanoma, all uveal melanomas should be managed as the more aggressive tumors (ie., those determined to be class 2 by expression profiling and those with monosomy 3) [<xref ref-type="bibr" rid="bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Malignant mesothelioma</bold>. MMe is highly refractory to conventional therapies including aggressive surgical intervention and multimodality strategies; thus, a cure is unlikely.</p>
            </list-item>
            <list-item>
              <p><bold>Clear cell renal cell carcinoma</bold> is treated in the usual manner.</p>
            </list-item>
          </list>
        </sec>
        <sec id="bap1-tpds.Prevention_of_Primary_Manifest">
          <title>Prevention of Primary Manifestations</title>
          <p><bold>Uveal melanoma.</bold> Arc welding has been associated with risk of uveal melanoma and this should be avoided if possible.</p>
          <p>Sunglasses with high UVA and UVB protection can reduce risk of cancer on the eyelids, but data regarding the benefit of sunglasses for uveal melanoma are lacking.</p>
          <p><bold>Malignant mesothelioma.</bold> As with all individuals, asbestos exposure and smoking should also be avoided.</p>
          <p><bold>Cutaneous melanoma.</bold> Primary prevention is limited to those measures typically used to reduce the risk for cutaneous melanoma, including limiting of sun exposure, regular use of sunscreen and protective clothing, and regular dermatologic examinations.</p>
        </sec>
        <sec id="bap1-tpds.Surveillance">
          <title>Surveillance</title>
          <p>Consensus management recommendations have not been established; however, several groups have proposed variations of the following [<xref ref-type="bibr" rid="bap1-tpds.REF.carbone.2012.179">Carbone et al 2012</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.battaglia.2014.37">Battaglia 2014</xref>, <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Uveal melanoma.</bold> Yearly dilated eye examinations and imaging by an ocular oncologist beginning around age 11 years</p>
            </list-item>
            <list-item>
              <p><bold>Malignant mesothelioma.</bold> No reliable early disease symptoms or screening modalities</p>
              <p>Annual evaluation is recommended for late manifestations of mesothelioma, which can include chest pain, cough, fever, shortness of breath, dysphagia, hoarseness, weight loss, fever, upper body and face edema (chest mesothelioma) and abdominal pain, ascites, nausea, vomiting, and/or constipation (peritoneal mesothelioma). Annual physical examination is recommended to look for signs of pleurisy (pleural inflammation), peritonitis, ascites and/or pleural effusion.</p>
              <p>If an abdominal MRI is to be performed as recommended for ccRCC, consider evaluation of the peritoneum and pleura as well. Although some physicians recommend spiral chest CT for asymptomatic persons with a history of exposure to asbestos, others do not, given the possible increased risk of cancer from radiation exposure.</p>
            </list-item>
            <list-item>
              <p><bold>Cutaneous melanoma, basal cell carcinoma and atypical Spitz tumors.</bold> Annual full body dermatologic examinations beginning around age 20 years</p>
            </list-item>
            <list-item>
              <p><bold>Clear cell renal cell carcinoma.</bold> Protocol similar to <related-object link-type="booklink" source-id="gene" document-id="vhl" document-type="chapter">von Hippel Lindau disease</related-object> with annual abdominal ultrasound examination; consideration of annual urinalysis and abdominal MRI every two years</p>
            </list-item>
          </list>
        </sec>
        <sec id="bap1-tpds.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Arc welding</p>
            </list-item>
            <list-item>
              <p>Asbestos</p>
            </list-item>
            <list-item>
              <p>Smoking</p>
            </list-item>
            <list-item>
              <p>Unnecessary and prolonged sun exposure</p>
            </list-item>
          </list>
        </sec>
        <sec id="bap1-tpds.Evaluation_of_Relatives_at_Ris">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an affected individual by molecular genetic testing for the <italic toggle="yes">BAP1</italic> pathogenic variant in the family in order to identify as early as possible those who would benefit from prompt initiation of screening and preventive measures.</p>
          <p>See <xref ref-type="sec" rid="bap1-tpds.Related_Genetic_Counseling_Iss">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="bap1-tpds.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Currently no open treatment trials specifically target patients with <italic toggle="yes">BAP1</italic>-TPDS.</p>
          <p>One NCI-sponsored <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01587352?term=bap1&#x00026;rank=3">trial</ext-link> using vorinostat in the treatment of metastatic uveal melanoma is assessing <italic toggle="yes">BAP1</italic> mutation status as a secondary outcome measure.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="bap1-tpds.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="bap1-tpds.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">BAP1</italic> tumor predisposition syndrome <italic toggle="yes">(BAP1</italic>-TPDS) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="bap1-tpds.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>To date, most individuals diagnosed with <italic toggle="yes">BAP1</italic>-TPDS have an affected parent. An affected parent may have <italic toggle="yes">BAP1</italic>-related tumors that differ from those of the proband.</p>
            </list-item>
            <list-item>
              <p>Some individuals diagnosed with <italic toggle="yes">BAP1</italic>-TPDS may have the disorder as the result of a <italic toggle="yes">de novo</italic> germline <italic toggle="yes">BAP1</italic> pathogenic variant. The proportion of <italic toggle="yes">BAP1</italic>-TPDS caused by a <italic toggle="yes">de novo</italic> pathogenic variant is unknown.</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing is recommended for the parents of a proband with an apparent <italic toggle="yes">de novo</italic> germline <italic toggle="yes">BAP1</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>If the germline <italic toggle="yes">BAP1</italic> pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, possible explanations include a <italic toggle="yes">de novo</italic> pathogenic variant in the proband or germline mosaicism in a parent (although no instances of germline mosaicism have been reported to date, it remains a possibility).</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with <italic toggle="yes">BAP1</italic>-TPDS may appear to be negative because of failure to recognize the disorder in family members, reduced penetrance, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless molecular genetic testing has confirmed that neither of the parents has the germline <italic toggle="yes">BAP1</italic> pathogenic variant identified in the proband.</p>
            </list-item>
            <list-item>
              <p>Note: If the parent is the individual in whom the pathogenic variant first occurred, s/he may have somatic mosaicism (including the germline) for the variant and may never have developed a <italic toggle="yes">BAP1</italic>-related tumor; however, this has not been reported to date for <italic toggle="yes">BAP1</italic>-TPDS.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband has the <italic toggle="yes">BAP1</italic> pathogenic variant, the risk to the sibs of inheriting the variant is 50%. However, penetrance appears to be incomplete (see <xref ref-type="sec" rid="bap1-tpds.Penetrance">Penetrance</xref>) and the types of <italic toggle="yes">BAP1</italic>-related tumors can vary among different members of the same family.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk for <italic toggle="yes">BAP1</italic>-TPDS because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">BAP1</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of parental germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with <italic toggle="yes">BAP1</italic>-TPDS has a 50% chance of inheriting the <italic toggle="yes">BAP1</italic> pathogenic variant. However, penetrance appears to be incomplete and the types of <italic toggle="yes">BAP1</italic>-related tumors can vary among different members of the same family.</p>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents: if a parent has the germline <italic toggle="yes">BAP1</italic> pathogenic variant, his or her family members may be at risk.</p>
        </sec>
        <sec id="bap1-tpds.Related_Genetic_Counseling_Iss">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="bap1-tpds.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior identification of the germline <italic toggle="yes">BAP1</italic> pathogenic variant in the family.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p>
          <p><bold>Genetic cancer risk assessment and counseling.</bold> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without molecular genetic testing, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</ext-link> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="bap1-tpds.Prenatal_Testing_and_Preimplan">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once a germline <italic toggle="yes">BAP1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk for <italic toggle="yes">BAP1</italic>-TPDS and preimplantation genetic diagnosis are possible options.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="bap1-tpds.Resources">
        <title>Resources</title>
      </sec>
      <sec id="bap1-tpds.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="bap1-tpds.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Although it has been been suggested that BAP1 functions as a tumor suppressor, this has not been completely established [<xref ref-type="bibr" rid="bap1-tpds.REF.kadariya.2016.2836">Kadariya et al 2016</xref>]. It is a nuclear-localized deubiquitinating enzyme and acts as a chromatin-associated protein that is part of large multi-protein complexes which both positively and negatively regulate cellular proliferation [reviewed in <xref ref-type="bibr" rid="bap1-tpds.REF.daou.2015.28643">Daou et al 2015</xref>]. It is recruited to promoter regions of genes involved in cellular proliferation to activate transcription and to promote repair at sites of DNA double strand breaks through homologous recombination [<xref ref-type="bibr" rid="bap1-tpds.REF.daou.2015.28643">Daou et al 2015</xref>].</p>
          <p><bold>Gene structure.</bold> The <italic toggle="yes">BAP1</italic> transcript <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_004656.3">NM_004656.3</ext-link> has 3717 base pairs and 17 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bap1-tpds" object-id="bap1-tpds.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> Reported pathogenic (cancer-predisposing) variants include missense, nonsense, and splicing variants and small deletions and duplications (see <related-object source-id="gene" document-id="bap1-tpds" object-id="bap1-tpds.molgen.TA">Table A</related-object>, <bold>HGMD</bold>).</p>
          <p>One apparent <italic toggle="yes">BAP1</italic> founder variant has been reported in four American families of German origin [<xref ref-type="bibr" rid="bap1-tpds.REF.carbone.2015.e1005633">Carbone et al 2015</xref>].</p>
          <p><bold>Normal gene product.</bold> The human BAP1 protein <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_004647.1">NP_004647.1</ext-link> has 729 amino acids. Critical domains include: ubiquitin C-terminal hydrolase, BARD binding, HCF1 binding, ASXL1/2 binding, an ATM-dependent serine 592 phosphorylation site, and BRCA1 binding, as well as a nuclear localizing signal.</p>
          <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">BAP1</italic>-TPDS is caused by a cancer-predisposing variant in one <italic toggle="yes">BAP1</italic> allele resulting in haploinsufficiency of the tumor suppressor protein BAP1. Tumors develop from certain cell types in which the second allele undergoes somatic mutation resulting in a complete absence of BAP1 tumor suppressor activity. Most atypical Spitz tumors (ASTs) analyzed by <xref ref-type="bibr" rid="bap1-tpds.REF.wiesner.2012.818">Wiesner et al [2012]</xref> showed loss of the remaining normal <italic toggle="yes">BAP1</italic> allele by various somatic alterations and all showed loss of BAP1 protein in the nucleus.</p>
          <sec id="bap1-tpds.Cancer_and_Benign_Tumors">
            <title>Cancer and Benign Tumors</title>
            <p>Sporadic tumors (including cholangiocarcinoma, mesothelioma, renal cell carcinoma and uveal melanoma) may occur as single tumors in the absence of any other findings of <italic toggle="yes">BAP1</italic>-TPDS and frequently harbor somatic variants in <italic toggle="yes">BAP1</italic> that are not present in the germline [reviewed in <xref ref-type="bibr" rid="bap1-tpds.REF.rai.2016.285">Rai et al 2016</xref>]. In these circumstances predisposition to these tumors is not heritable.</p>
          </sec>
        </sec>
      </sec>
      <sec id="bap1-tpds.References">
        <title>References</title>
        <sec id="bap1-tpds.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="bap1-tpds.Literature_Cited.reflist0">
            <ref id="bap1-tpds.REF.abdelrahman.2011.856">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abdel-Rahman</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pilarski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cebulla</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massengill</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christopher</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovland</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidorf</surname>
                    <given-names>FH</given-names>
                  </name>
                </person-group>
                <article-title>Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma and other cancers.</article-title>
                <source>J Med Genet.</source>
                <year>2011</year>
                <volume>48</volume>
                <fpage>856</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21941004</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.aoude.2015.126">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aoude</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gartside</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johansson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Symmons</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayward</surname>
                    <given-names>NK</given-names>
                  </name>
                </person-group>
                <article-title>Prevalence of germline BAP1, CDKN2A, and CDK4 mutations in an Australian population-based sample of cutaneous melanoma cases.</article-title>
                <source>Twin Res Hum Genet.</source>
                <year>2015</year>
                <volume>18</volume>
                <fpage>126</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">25787093</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.aoude.2013a.278">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aoude</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vajdic</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kricker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armstrong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayward</surname>
                    <given-names>NK</given-names>
                  </name>
                </person-group>
                <article-title>Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases.</article-title>
                <source>Pigment Cell Melanoma Res</source>
                <year>2013a</year>
                <volume>26</volume>
                <fpage>278</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23171164</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.aoude.2013b.e72144">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aoude</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wadt</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bojesen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cr&#x000fc;ger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trent</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerdes</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000f6;nsson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayward</surname>
                    <given-names>NK. A</given-names>
                  </name>
                </person-group>
                <article-title>BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.</article-title>
                <source>PLoS One.</source>
                <year>2013b</year>
                <volume>8</volume>
                <fpage>e72144</fpage>
                <pub-id pub-id-type="pmid">23977234</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.battaglia.2014.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Battaglia</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment.</article-title>
                <source>Clin Med Insights Oncol.</source>
                <year>2014</year>
                <volume>8</volume>
                <fpage>37</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">24855403</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.baumann.2015.76">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flores</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Napolitano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanodia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taioli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pass</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.</article-title>
                <source>Carcinogenesis.</source>
                <year>2015</year>
                <volume>36</volume>
                <fpage>76</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">25380601</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.betti.2015.51">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Betti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casalone</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrante</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romanelli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grosso</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guarrera</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Righi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vatrano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelosi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Libener</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirabelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boldorini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casadio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papotti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matullo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dianzani</surname>
                    <given-names>I.</given-names>
                  </name>
                </person-group>
                <article-title>Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.</article-title>
                <source>Genes Chrom Cancer</source>
                <year>2015</year>
                <volume>54</volume>
                <fpage>51</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">25231345</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.carbone.2012.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferris</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Napolitano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lum</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flores</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant-Greenwood</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krausz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyjek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tate</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedberg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weigel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pass</surname>
                    <given-names>HI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.</article-title>
                <source>J Transl Med.</source>
                <year>2012</year>
                <volume>10</volume>
                <fpage>179</fpage>
                <pub-id pub-id-type="pmid">22935333</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.carbone.2015.e1005633">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flores</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsunoda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Behner</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hesdorffer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nasu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Napolitano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minaai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant-Greenwood</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lauk</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirschner</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weder</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opitz</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pass</surname>
                    <given-names>HI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastorino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s.</article-title>
                <source>PLoS Genet.</source>
                <year>2015</year>
                <volume>11</volume>
                <fpage>e1005633</fpage>
                <pub-id pub-id-type="pmid">26683624</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.cheung.2015.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cheung</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadariya</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talarchek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohar</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kayaleh</surname>
                    <given-names>OR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.</article-title>
                <source>Cancer Lett.</source>
                <year>2015</year>
                <volume>369</volume>
                <fpage>261</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">26409435</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.daou.2015.28643">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daou</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammond-Martel</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mashtalir</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbour</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagnon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannantuono</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nkwe</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motorina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pak</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wurtele</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milot</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mallette</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Affar el B. The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer.</article-title>
                <source>J Biol Chem.</source>
                <year>2015</year>
                <volume>290</volume>
                <fpage>28643</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">26416890</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.de_la_fouchardi_re.2015b.921">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de la Fouchardi&#x000e8;re</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabaret</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petre</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aydin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Potter</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pissaloux</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddad</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janin</surname>
                    <given-names>N.</given-names>
                  </name>
                </person-group>
                <article-title>Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome.</article-title>
                <source>Acta Neuropathol</source>
                <year>2015b</year>
                <volume>129</volume>
                <fpage>921</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">25900292</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.de_la_fouchardi_re.2015a.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de la Fouchardi&#x000e8;re</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabaret</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Combemale</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schvartz</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonadona</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soufir</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Germline BAP1 mutations predispose also to multiple basal cell carcinomas.</article-title>
                <source>Clin Genet.</source>
                <year>2015a</year>
                <volume>88</volume>
                <fpage>273</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">25080371</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.de_reyni_s.2014.1323">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Reyni&#x000e8;s</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaurand</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couchy</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hysi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elarouci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galateau-Sall&#x000e9;</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copin</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andujar</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imbeaud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pairon</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Pimpec-Barthes</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zucman-Rossi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jean</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.</article-title>
                <source>Clin Cancer Res.</source>
                <year>2014</year>
                <volume>20</volume>
                <fpage>1323</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">24443521</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.farley.2013.1061">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Farley</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pe&#x000f1;a-Llopis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavia-Jimenez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vocke</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricketts</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Middelton</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinch</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grishin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merino</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metwalli</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xing</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>XJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linehan</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugarolas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.</article-title>
                <source>Mol Cancer Res.</source>
                <year>2013</year>
                <volume>11</volume>
                <fpage>1061</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">23709298</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.gupta.2015.881">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeAngelis</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayne</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crabtree</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gragoudas</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>IK</given-names>
                  </name>
                </person-group>
                <article-title>Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations.</article-title>
                <source>JAMA Ophthalmol.</source>
                <year>2015</year>
                <volume>133</volume>
                <fpage>881</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">25974357</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.haas.2014.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nathanson</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary kidney cancer syndromes.</article-title>
                <source>Adv Chronic Kidney Dis</source>
                <year>2014</year>
                <volume>21</volume>
                <fpage>81</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">24359990</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.iscovich.2002.42">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iscovich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdulrazik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cour</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischbein</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pe'er</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldgar</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <article-title>Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients.</article-title>
                <source>Int J Cancer</source>
                <year>2002</year>
                <volume>98</volume>
                <fpage>42</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">11857383</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.kadariya.2016.2836">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kadariya</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheung</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sementino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menges</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cai</surname>
                    <given-names>KQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rauscher</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein-Szanto</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations.</article-title>
                <source>Cancer Res.</source>
                <year>2016</year>
                <volume>76</volume>
                <fpage>2836</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">26896281</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.kalirai.2014.1373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kalirai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dodson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faqir</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damato</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coupland</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.</article-title>
                <source>Br J Cancer</source>
                <year>2014</year>
                <volume>111</volume>
                <fpage>1373</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">25058347</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.kumar.2015.1089">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miao</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ji</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Njauw</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000f6;nsson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frederick</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsao</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>BAP1 has a survival role in cutaneous melanoma.</article-title>
                <source>J Invest Dermatol</source>
                <year>2015</year>
                <volume>135</volume>
                <fpage>1089</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">25521456</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.marzukaalcal_.2014.381">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marzuka-Alcal&#x000e1;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabree</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsao</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Melanoma Susceptibility Genes and Risk Assessment.</article-title>
                <source>Methods Mol Biol.</source>
                <year>2014</year>
                <volume>1102</volume>
                <fpage>381</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">24258989</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.mcdonnell.2016.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McDonnell</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallanis</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heller</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Idos</surname>
                    <given-names>GI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Culver</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>S-E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peng</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruber</surname>
                    <given-names>SB</given-names>
                  </name>
                </person-group>
                <article-title>A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer.</article-title>
                <source>Cancer Genet</source>
                <year>2016</year>
                <volume>209</volume>
                <fpage>75</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">26774355</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.mochel.2015.901">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mochel</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piris</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nose</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoang</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <article-title>Loss of BAP1 expression in basal cell carcinomas in patients with germline BAP1 mutations.</article-title>
                <source>Am J Clin Pathol.</source>
                <year>2015</year>
                <volume>143</volume>
                <fpage>901</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">25972334</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.njauw.2012.e35295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Njauw</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piris</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabree</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeAngelis</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gragoudas</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duncan</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsao</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.</article-title>
                <source>PLoS One</source>
                <year>2012</year>
                <volume>7</volume>
                <fpage>e35295</fpage>
                <pub-id pub-id-type="pmid">22545102</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.ohar.2016.206">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ohar</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheung</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talarchek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hesdorffer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peng</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rauscher</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer.</article-title>
                <source>Cancer Res.</source>
                <year>2016</year>
                <volume>76</volume>
                <fpage>206</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">26719535</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.pe_allopis.2012.751">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pe&#x000f1;a-Llopis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vega-Rub&#x000ed;n-de-Celis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leng</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pav&#x000ed;a-Jim&#x000e9;nez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamasaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhrebker</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sivanand</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spence</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinch</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hambuch</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jain</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lotan</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margulis</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sagalowsky</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Summerour</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kabbani</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grishin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laurent</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>XJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haudenschild</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bentley</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kapur</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugarolas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>BAP1 loss defines a new class of renal cell carcinoma.</article-title>
                <source>Nat Genet.</source>
                <year>2012</year>
                <volume>44</volume>
                <fpage>751</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22683710</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.pilarski.2014.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pilarski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cebulla</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massengill</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rich</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGillivray</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asrat</surname>
                    <given-names>M-J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carbon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidorf</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdel-Rahman</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <article-title>Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome.</article-title>
                <source>Genes Chromosomes Cancer.</source>
                <year>2014</year>
                <volume>53</volume>
                <fpage>177</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">24243779</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.popova.2013.974">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Popova</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hebert</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquemin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caux-Moncoutier</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubois-d'Enghien</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richaudeau</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renaudin</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sellers</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sastre-Garau</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desjardins</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gyapay</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raynal</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinilnikova</surname>
                    <given-names>OM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrieu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mani&#x000e9;</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Pauw</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gesta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonadona</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maugard</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avril</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barillot</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabaret</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delattre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benfodda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soufir</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoppa-Lyonnet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stern</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <article-title>Germline BAP1 mutations predispose to renal cell carcinomas.</article-title>
                <source>Am J Hum Genet</source>
                <year>2013</year>
                <volume>92</volume>
                <fpage>974</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">23684012</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.rai.2016.285">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pilarski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cebulla</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdel-Rahman</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <article-title>Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.</article-title>
                <source>Clin Genet</source>
                <year>2016</year>
                <volume>89</volume>
                <fpage>285</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">26096145</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.rusch.2014.271">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rusch</surname>
                    <given-names>VW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krug</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <article-title>The challenge of malignant pleural mesothelioma: new directions.</article-title>
                <source>J Thorac Oncol.</source>
                <year>2014</year>
                <volume>9</volume>
                <fpage>271</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">24518084</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.scott.2002.188">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vajdic</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armstrong</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ainsworth</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meldrum</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aitken</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kricker</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>BRCA2 mutations in a population-based series of patients with ocular melanoma.</article-title>
                <source>Int J Cancer</source>
                <year>2002</year>
                <volume>102</volume>
                <fpage>188</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">12385017</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.singhi.2016.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singhi</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krasinskas</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choudry</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartlett</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pingpank</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeh</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luvison</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuhrer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bahary</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seethala</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dacic</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.</article-title>
                <source>Mod Pathol.</source>
                <year>2016</year>
                <volume>29</volume>
                <fpage>14</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">26493618</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.sinilnikova.1999.325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sinilnikova</surname>
                    <given-names>OM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egan</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinn</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boutrand</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoppa-Lyonnet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desjardins</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldgar</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gragoudas</surname>
                    <given-names>ES</given-names>
                  </name>
                </person-group>
                <article-title>Germline brca2 sequence variants in patients with ocular melanoma.</article-title>
                <source>Int J Cancer</source>
                <year>1999</year>
                <volume>82</volume>
                <fpage>325</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10399947</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.sneddon.2015.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sneddon</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leon</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dick</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cadby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brims</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allcock</surname>
                    <given-names>RJN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moses</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melton</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Klerk</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musk</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BWS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Creaney</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.</article-title>
                <source>Gene</source>
                <year>2015</year>
                <volume>563</volume>
                <fpage>103</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">25796603</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.testa.2011.1022">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheung</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Below</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sementino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dogan</surname>
                    <given-names>AU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pass</surname>
                    <given-names>HI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trusa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hesdorffer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nasu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comertpay</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanji</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Germline BAP1 mutations predispose to malignant mesothelioma.</article-title>
                <source>Nat Genet.</source>
                <year>2011</year>
                <volume>43</volume>
                <fpage>1022</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21874000</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.turunen.2016.1112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turunen</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markkinen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilska</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saarinen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raivio</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>T&#x000e4;ll</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kivel&#x000e4;</surname>
                    <given-names>TT</given-names>
                  </name>
                </person-group>
                <article-title>BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma.</article-title>
                <source>Ophthalmology.</source>
                <year>2016</year>
                <volume>123</volume>
                <fpage>1112</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">26876698</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.wadt.2012.815">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wadt</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiilgaard</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heegaard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drzewiecki</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trent</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hewitt</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayward</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerdes</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <article-title>A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.</article-title>
                <source>Pigment Cell Melanoma Res.</source>
                <year>2012</year>
                <volume>25</volume>
                <fpage>815</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22889334</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.wadt.2015.267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wadt</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoude</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johansson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solinas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pritchard</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crainic</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiilgaard</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heegaard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunde</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federspiel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madore</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCarthy</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodwin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000f6;nsson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Busam</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trent</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerdes</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scolyer</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayward</surname>
                    <given-names>NK</given-names>
                  </name>
                </person-group>
                <article-title>A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.</article-title>
                <source>Clin Genet.</source>
                <year>2015</year>
                <volume>88</volume>
                <fpage>267</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">25225168</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.wiesner.2012.818">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wiesner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murali</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fried</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerroni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Busam</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutzner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastian</surname>
                    <given-names>BC</given-names>
                  </name>
                </person-group>
                <article-title>A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.</article-title>
                <source>Am J Surg Pathol.</source>
                <year>2012</year>
                <volume>36</volume>
                <fpage>818</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">22367297</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.wiesner.2011.1018">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wiesner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obenauf</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murali</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fried</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griewank</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ulz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windpassinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wackernagel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viale</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lash</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Socci</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000fc;tten</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmedo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abramson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Offit</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ott</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerroni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutzner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastian</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speicher</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <article-title>Germline mutations in BAP1 predispose to melanocytic tumors.</article-title>
                <source>Nat Genet.</source>
                <year>2011</year>
                <volume>43</volume>
                <fpage>1018</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">21874003</pub-id>
              </element-citation>
            </ref>
            <ref id="bap1-tpds.REF.xu.2014.4388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadariya</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheung</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talarchek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sementino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menges</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cai</surname>
                    <given-names>KQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Litwin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peng</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rauscher</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.</article-title>
                <source>Cancer Res.</source>
                <year>2014</year>
                <volume>74</volume>
                <fpage>4388</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">24928783</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="bap1-tpds.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="bap1-tpds.Author_Notes">
          <title>Author Notes</title>
          <p>Author&#x02019;s <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://eye.osu.edu/research/articles/melanoma/">website</ext-link></p>
          <p>Our group&#x02019;s research is focused on identifying and characterizing hereditary causes of uveal melanoma. We were one of three groups co-reporting on the identification of the <italic toggle="yes">BAP1</italic> tumor predisposition syndrome. We offer research analysis of <italic toggle="yes">BAP1</italic> in families with histories suggestive of <italic toggle="yes">BAP1</italic>-TPDS and are performing exome and other analyses on high-risk UM families without identifiable genetic causes. To discuss enrolling a patient please contact <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="robert.pilarski@osumc.edu">robert.pilarski@osumc.edu</email>.</p>
        </sec>
        <sec id="bap1-tpds.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>13 October 2016 (bp) Review posted live</p>
            </list-item>
            <list-item>
              <p>3 May 2016 (rp) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
